Petra Sonder1, Gladys N Janssens1, Albertus Beishuizen2, Connie L Henry3, Jon C Rittenberger4, Clifton W Callaway4, Cameron Dezfulian4, Kees H Polderman5. 1. Department of Critical Care Medicine, University of Pittsburgh Medical Center, 200 Lothrop St, Pittsburgh, PA 15213, United States. 2. Department of Critical Care Medicine, VU University Medical Center, PO Box 7075, 1007 MB Amsterdam, The Netherlands; Department of Critical Care Medicine, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The Netherlands. 3. UPMC Mercy Hospital, University of Pittsburgh School of Medicine, 1400 Locust St, Pittsburgh, PA 15219, United States. 4. Department of Emergency Medicine, University of Pittsburgh Medical Center, 3600 Forbes Avenue, Suite 400A, Pittsburgh, PA 15261, United States. 5. Department of Critical Care Medicine, University of Pittsburgh Medical Center, 200 Lothrop St, Pittsburgh, PA 15213, United States. Electronic address: k.polderman@tip.nl.
Abstract
BACKGROUND: Mild therapeutic hypothermia (32-36 °C) is associated with improved outcomes in patients with brain injury after cardiac arrest (CA). Various devices are available to induce and maintain hypothermia, but few studies have compared the performance of these devices. We performed a prospective study to compare four frequently used cooling systems in inducing and maintaining hypothermia followed by controlled rewarming. METHODS: We performed a prospective multi-centered study in ten ICU's in three hospitals within the UPMC health system. Four different cooling technologies (seven cooling methods in total) were studied: two external water-circulating cooling blankets (Meditherm® and Blanketrol®), gel-coated adhesive cooling pads (Arctic Sun®), and endovascular cooling catheters with balloons circulating ice-cold saline (Thermogard®). For the latter system we studied three different types of catheter with two, three or four water-circulating balloons, respectively. In contrast to previous studies, we not only studied the cooling rate (i.e., time to target temperature) in the induction phase, but also the percentage of the time during the maintenance phase that temperature was on target ±0.5 °C, and the efficacy of devices to control rewarming. We believe that these are more important indicators of device performance than induction speed alone. RESULTS: 129 consecutive patients admitted after CA and treated with hypothermia were screened, and 120 were enrolled in the study. Two researchers dedicated fulltime to this study monitored TH treatment in all patients, including antishivering measures, additional cooling measures used (e.g. icepacks and cold fluid infusion), and all other issues related to temperature management. Baseline characteristics were similar for all groups. Cooling rates were 2.06 ± 1.12 °C/h for endovascular cooling, 1.49 ± 0.82 for Arctic sun, 0.61 ± 0.36 for Meditherm and 1.22 ± 1.12 for Blanketrol. Time within target range ±0.5 °C was 97.3 ± 6.0% for Thermogard, 81.8 ± 25.2% for Arctic Sun, 57.4 ± 29.3% for Meditherm, and 64.5 ± 20.1% for Blanketrol. The following differences were significant: Thermogard vs. Meditherm (p < 0.01), Thermogard vs. Blanketrol (p < 0.01), and Arctic Sun vs. Meditherm (p < 0.02). No major complications occurred with any device. CONCLUSIONS: Endovascular cooling and gel-adhesive pads provide more rapid hypothermia induction and more effective temperature maintenance compared to water-circulating cooling blankets. This applied to induction speed, but (more importantly) also to time within target range during maintenance.
BACKGROUND: Mild therapeutic hypothermia (32-36 °C) is associated with improved outcomes in patients with brain injury after cardiac arrest (CA). Various devices are available to induce and maintain hypothermia, but few studies have compared the performance of these devices. We performed a prospective study to compare four frequently used cooling systems in inducing and maintaining hypothermia followed by controlled rewarming. METHODS: We performed a prospective multi-centered study in ten ICU's in three hospitals within the UPMC health system. Four different cooling technologies (seven cooling methods in total) were studied: two external water-circulating cooling blankets (Meditherm® and Blanketrol®), gel-coated adhesive cooling pads (Arctic Sun®), and endovascular cooling catheters with balloons circulating ice-cold saline (Thermogard®). For the latter system we studied three different types of catheter with two, three or four water-circulating balloons, respectively. In contrast to previous studies, we not only studied the cooling rate (i.e., time to target temperature) in the induction phase, but also the percentage of the time during the maintenance phase that temperature was on target ±0.5 °C, and the efficacy of devices to control rewarming. We believe that these are more important indicators of device performance than induction speed alone. RESULTS: 129 consecutive patients admitted after CA and treated with hypothermia were screened, and 120 were enrolled in the study. Two researchers dedicated fulltime to this study monitored TH treatment in all patients, including antishivering measures, additional cooling measures used (e.g. icepacks and cold fluid infusion), and all other issues related to temperature management. Baseline characteristics were similar for all groups. Cooling rates were 2.06 ± 1.12 °C/h for endovascular cooling, 1.49 ± 0.82 for Arctic sun, 0.61 ± 0.36 for Meditherm and 1.22 ± 1.12 for Blanketrol. Time within target range ±0.5 °C was 97.3 ± 6.0% for Thermogard, 81.8 ± 25.2% for Arctic Sun, 57.4 ± 29.3% for Meditherm, and 64.5 ± 20.1% for Blanketrol. The following differences were significant: Thermogard vs. Meditherm (p < 0.01), Thermogard vs. Blanketrol (p < 0.01), and Arctic Sun vs. Meditherm (p < 0.02). No major complications occurred with any device. CONCLUSIONS: Endovascular cooling and gel-adhesive pads provide more rapid hypothermia induction and more effective temperature maintenance compared to water-circulating cooling blankets. This applied to induction speed, but (more importantly) also to time within target range during maintenance.
Authors: Yew Woon Chia; Shir Lynn Lim; Julian Kenrick Loh; Benjamin Sieu-Hon Leong; Marcus Eng Hock Ong Journal: Singapore Med J Date: 2021-08 Impact factor: 1.858
Authors: Alicia M Alcamo; Rebecca Lavezoli; Cameron Dezfulian; Dennis W Simon; Rajesh K Aneja; Robert S B Clark; Patrick M Kochanek; Ericka L Fink Journal: Ther Hypothermia Temp Manag Date: 2020-05-19 Impact factor: 1.286
Authors: Mehdi Javanbakht; Atefeh Mashayekhi; Mohsen Rezaei Hemami; Michael Branagan-Harris; Thomas R Keeble; Mohsen Yaghoubi Journal: Pharmacoecon Open Date: 2022-05-03
Authors: Clifton W Callaway; Patrick J Coppler; John Faro; Jacob S Puyana; Pawan Solanki; Cameron Dezfulian; Ankur A Doshi; Jonathan Elmer; Adam Frisch; Francis X Guyette; Masashi Okubo; Jon C Rittenberger; Alexandra Weissman Journal: JAMA Netw Open Date: 2020-07-01
Authors: Lorenzo Calabró; Wulfran Bougouin; Alain Cariou; Chiara De Fazio; Markus Skrifvars; Eldar Soreide; Jacques Creteur; Hans Kirkegaard; Stéphane Legriel; Jean-Baptiste Lascarrou; Bruno Megarbane; Nicolas Deye; Fabio Silvio Taccone Journal: Crit Care Date: 2019-08-23 Impact factor: 9.097